

Meet the Network and Community Leadership
Network: Quantitative Pharmacology (QP)
Community: Pharmacometrics and Pharmacokinetics (PMK)



Community Chair:
Michael A. Tortorici,
PharmD
CSL Behring

Dr. Michael A. Tortorici is a Director of Clinical Pharmacology & Early Development at CSL Behring based in Philadelphia, PA, since 2014. Dr. Tortorici received his PharmD from the University of Pittsburgh in 2002 and his PhD in Pharmaceutical Sciences from the University of Pittsburgh in 2007. Dr. Tortorici started his career with Pfizer La Jolla, CA in the Oncology Clinical Pharmacology group (2007-2011) and then with Pfizer in Collegeville, PA in Specialty Care (2011-2014). His research focus has been on the application of pharmacometric approaches for dose selection and individualized dosing with large molecules in the therapeutic areas of inflammation, immunology and cardiovascular medicine. In addition, he has published numerous papers on the topic of assessment of pharmacokinetics in kidney disease and the utility of modeling & simulation to assess PK in kidney disease.

Dr. Tortorici is currently the American Society of Clinical Pharmacology & Therapeutics (ASCPT) Vice Chair of the Pharmacometrics & Pharmacokinetics (PMK) Community. He has previously served on the Scientific Program Committee for ASCPT (2013-2015). He has served on the Steering Committee of the PMK section of AAPS (2014-2017).